MacroGenics, Inc. (MGNX) Stock Grade

About MacroGenics, Inc.'s fundamentals

MacroGenics is a small-cap biotechnology company with a market capitalization of $101.7 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -49.9%. The company generated minimal revenue growth of 0.8% year-over-year, indicating stagnant top-line performance. As a development-stage biotech firm, MacroGenics does not pay dividends and lacks traditional profitability metrics such as a P/E ratio or positive return on equity. Investors should note that the company's financial structure is typical of early-stage biotechnology firms focused on research and development rather than current earnings generation.